← Leaderboards
Robert Kreitman
Basic Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Basic Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Hairy Cell Leukemia”
- Darell D Bigner · Duke University$6,599,382
- Omar Abdel-Wahab · Sloan-Kettering Inst Can Research$2,362,664
- Markus Mãschen · Yale University$1,894,432
- Susan M Parkhurst · Fred Hutchinson Cancer Research Center$1,778,573
- Jing Chen · University Of Chicago$1,712,078
- Christopher Y Park · Stanford University$1,328,488
Research focus
Hairy Cell LeukemiaImmunoglobulinsPseudomonasExotoxinsResponseHematologic NeoplasmsToxinCytotoxicityRituximabCellsRecombinantsB Lymphoid MalignancyDoseMutationCd22 GenePublishingTumor MarkersMolecularImmunotoxinsChemotherapyRelapseImmunogenicityCladribinePurine Analog
Grant awards (34)
Development of Recombinant Toxins to Treat Hematologic Malignancies$3,020,282
ZIA · FY2025 · CA · contact PI
Patterns of immune response in COVID-19 patients$61,638
ZIA · FY2025 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,588,137
ZIA · FY2024 · CA · contact PI
Patterns of immune response in COVID-19 patients$176,460
ZIA · FY2024 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,665,659
ZIA · FY2023 · CA · contact PI
Patterns of immune response in COVID-19 patients$185,073
ZIA · FY2023 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,340,622
ZIA · FY2022 · CA · contact PI
Patterns of immune response in COVID-19 patients$335,156
ZIA · FY2022 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,240,277
ZIA · FY2021 · CA · contact PI
Patterns of immune response in COVID-19 patients$413,425
ZIA · FY2021 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,202,567
ZIA · FY2020 · CA · contact PI
Patterns of immune response in COVID-19 patients$400,855
ZIA · FY2020 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,559,707
ZIA · FY2019 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,310,387
ZIA · FY2018 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,036,808
ZIA · FY2017 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,307,015
ZIA · FY2016 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,065,252
ZIA · FY2015 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$1,241,003
ZIA · FY2014 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$949,264
ZIA · FY2013 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$991,402
ZIA · FY2012 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$754,944
ZIA · FY2011 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$791,642
ZIA · FY2010 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$683,093
ZIA · FY2009 · CA · contact PI
Development of Recombinant Toxins to Treat Hematologic Malignancies$744,746
Z01 · FY2008 · CA · contact PI
Development of Recombinant Toxins for Treatment of Patients with Hematologic Mal$742,753
Z01 · FY2007 · CA · contact PI
Development of Recombinant Toxins for Treatment of Patie$0
Z01 · FY2006 · BC · contact PI
Development of Recombinant Toxins for Treatment of Patie$0
Z01 · FY2005 · BC
Recombinant Toxins for Treatment of Patients$0
Z01 · FY2004 · BC
Development of Recombinant Toxins for Treatment of Patie$0
Z01 · FY2003 · BC
Recombinant Toxins for Treatment of Hematologic Neoplasm$0
Z01 · FY2002 · BC
Immunotoxin Therapy for Solid Tumors: Clinical studies$0
Z01 · FY2001 · SC
Development of Recombinant Toxins for Treatment of Patie$0
Z01 · FY2001 · BC
IMMUNOTOXIN THERAPY FOR SOLID TUMORS: CLINICAL STUDIES$0
Z01 · FY2000 · SC
Development of Recombinant Toxins for Treatment of Patients with Hematologic Mal$0
Z01 · FY2000 · BC